# Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

> **NCT03235245** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 271 (actual)

## Conditions studied

- Unresectable Stage III Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** Nivolumab + Ipilimumab
- **DRUG:** Encorafenib + Binimetinib

## Key facts

- **NCT ID:** NCT03235245
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-30
- **Primary completion:** 2023-10-24
- **Final completion:** 2027-01
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235245, "Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03235245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*